肺络通合剂对肺纤维化大鼠肺组织病理形态学 和纤维连接蛋白含量的影响

目的:探讨肺络通合剂对肺纤维化大鼠肺组织病理形态学的影响。方法:选择Wistar大白鼠,气管内注入博莱霉素建立肺纤维化模型。随机分为正常对照组、模型组、中药高、低剂量组和强的松组。除正常对照组外,其余4组均制成肺纤维化动物模型,模型组用生理盐水ig,中药高、低剂量组用肺络通合剂(相当于生药18,9 g.kg-1)ig。强的松组用强的松(2.04mg.kg-1)ig。各组于用药后28,56 d各随机处死一半大鼠取材送检,观察肺泡炎症病理变化,肺纤维化病理变化和纤维连接蛋白(FN)含量。结果:模型组大量胶原纤维增生,呈重度肺纤维化改变,平均病理积分(56 d,下同)为2.50±0.71;肺络通合剂高剂量组呈轻度肺纤维化(1.00±0.82);低剂量组(1.50±0.85)病变程度较中药高剂量组略重,强的松组(1.80±0.92)病变程度较模型组轻,但较中药高剂量组为重;FN含量平均A值(28 d)肺络通高剂量组(49.55±6.57)明显低于模型组(272.11±40.12),且作用优于强的松组(73.25±11.11)。结论:肺络通合剂能有效抑制博莱霉素引起的肺纤维化形成。

Influence of Feiluotong Mistura on Pathomorphological Changes and Fibronectin Content in Rats with Pulmonic Fibrosis

Objective: To observe the Pathomorphological changes in rats with pulmonic fibrosis treating by Feiluotong Mistura. Method: Wistar rats were divided into normal group, model group, herbal therapy high dose group, herbal therapy low dose group, western medicine (WM) group. In addition to the normal group, the other four groups were reproduced animal model of pulmonic fibrosis. The model group were given normal saline gavage. The herbal therapy high dose group was given Feiluotong Mistura (18 g·kg^-1) gavage. The herbal therapy low dose group was given Feiluotong Mistura (9.0 g·kg^-1) gavage. WM group given prednisone gavage. Half of each group were taken lung to test in the 28^th day and the 56^th day. Result: Large collagen fibers hyperplasia was founded in the model group, a severe pulmonary fibrosis in WM group. Mild pulmonary fibrosis was founded in the herbal therapy high dose group, fibrosis in the herbal therapy low dose group was more severe than that in the herbal therapy high dose group, Lesions of WM group were milder than that of the model group. Conclusion: Feiluotong Mistura can effectively inhibit the formation of pulmonary fibrosis induced by bleocin.